Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer (BMS-247550)
Breast Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring stage IV breast cancer, stage IIIA breast cancer, recurrent breast cancer, stage IIIB breast cancer, stage III ovarian epithelial cancer, stage IV ovarian epithelial cancer, recurrent ovarian epithelial cancer, unspecified adult solid tumor, protocol specific, ovarian stromal cancer, stage III ovarian germ cell tumor, stage IV ovarian germ cell tumor, recurrent ovarian germ cell tumor, borderline ovarian surface epithelial-stromal tumor, ovarian sarcoma, male breast cancer
Eligibility Criteria
Inclusion Criteria: Histologically or cytologically confirmed metastatic or unresectable solid malignancy for which no standard or curative therapies exist or are no longer effective Metastatic, recurrent, or locally advanced breast, ovarian, or other cancer Hemoglobin at least 9.0 g/dL WBC at least 3,000/mm3 Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Bilirubin normal AST/ALT no greater than 3 times upper limit of normal Gilbert's syndrome allowed Creatinine no greater than 2 mg/dL Exclusion Criteria: symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia grade 2 or greater clinical neuropathy prior allergy or hypersensitivity reaction (grade 2 or greater) to prior paclitaxel or other therapy containing Cremophor EL allergy or intolerance to steroids, diphenhydramine, cimetidine, or ranitidine uncontrolled concurrent illness active infection pregnant or nursing other concurrent anticancer therapies or commercial agents other concurrent investigational agents other concurrent highly active antiretroviral therapy for HIV-positive patients
Sites / Locations
- Albert Einstein Clinical Cancer Center
- NYU School of Medicine's Kaplan Comprehensive Cancer Center
Arms of the Study
Arm 1
Experimental
Treated Participants
dose escalation treatment